Recent and Popular Releases
Tocagen Drug Candidate Looks Undervalue [March 18, 2018]
Syndax Pharmaceuticals Undervalued On Coming Data Readouts [February 15, 2018 @ Seeking Alpha]
Reata Pharmaceuticals A Buy On Bardoxolene Data [February 14, 2018 @ Seeking Alpha]
Celldex Value Depends on Coming Data [February 8, 2018 @ Seeking Alpha]
ImmunoGen Price Run-Up Driven by Potential Trial Data [Feb. 6, 2018 at SA]
Endocyte Has a Strong Phase 3 Ready Asset
[January 31, 2018 at Seeking Alpha]
William Meyers changes 2018 stocks covered
BiTE Amgen for Long-term Returns [December 16, 2017 @ Seeking Alpha]
Gilead Sciences Going Down When It Should Go Up [Seeking Alpha, 12/8/2017]
Celgene is Oversold [Seeking Alpha, 11/30/2017]
Incyte Q3 Result Could Be An Upward Inflection Point [Seeking Alpha, 11/2/2017]
Applied Materials Still A Buy After 59% YTD Gain [October 6, 2017 @ Seeking Alpha]
Evaluating AMD's Server Market Potential [July 7, 2017 at Seeking Alpha]
GlycoMimetics Remains Undervalued After Leukemia Data Release [June 14, 2017 at Seeking Alpha]
Biogen Key Q1 2017 Insights [April 26, 2017 @ Seeking Alpha]
Bioverativ Target Raised on 10-K Data [Seeking Alpha, March 27, 2017]
There Is No Stock Market [February 9, 2014]
William Meyers Adds Amgen, Intuitive Surgical to Coverage [Sep. 4, 2013]
William Meyers resumes coverage of Altera [at Seeking Alpha, July 18, 2013]
Dendreon Provenge Could See Survival Benefit Extension [April 18, 2013]
Akamai 2013 Outlook [March 12, 2013]
Celgene Sees Revenue Doubling by 2017 [January 26, 2013]
I buy Adept Technology (ADEP) [November 5, 2012]
Inovio Prospects [June 18, 2012]
Aping as the Basis of Intelligence [June 5, 2012]
Dell Using Marvell ARM for Servers [May 30, 2012]
Gilead Sciences Looks for Hepatitis C Cure [April 29, 2012]
AMD Guides to Strong 2012 [April 19, 2012]
Opportunities in Data Storage: STX, MRVL, HILL [April 12, 2012]
Red Hat Tipping Point? [March 29, 2012]
Adobe Waits for CS6 [March 20, 2012]
Dot Hill Expects New Clients in 2012 [March 15, 2012]
SGI Challenged by Analysts [February 8, 2012]
Marvell Technology Group Hones Edge [January 18, 2012]
2012 U.S. Economic Outlook [December 29, 2011]
Cantel Medical Record Quarter [December 12, 2011]
Slow Magellan Ramp Planned by Hansen Medical [Novermber 22, 2011]
Biogen Idec: Q3 Clues to Value [November 2, 2011]
Marvell Technology and Thailand Floods [October 19, 2011]
Cantel Medical Keeps Growing [September 28, 2011]
SGI Brain Modeling Slide [September 22, 2011]
Dendreon Restructuring Call [September 8, 2011]
Marvell Ramps TD Chip Revenue [August 28, 2011]
TTM Technologies Expands to Meet Demand [August 11, 2011]
Dendreon Provenge Demand Questioned [August 8, 2011]
Plenty of Stimulus [August 2, 2011]
Celgene Readies Arsenal [August 2, 2011]
Gilead Sciences Readies Pipeline [July 27, 2011]
Dendreon Ramps up Provenge Production [July 15, 2011]
Biogen Idec: Is there More Value? [July 11, 2011]
Hansen Medical: Valuation Thoughts [July 8, 2011]
Upside Potential of AMD Fusion [June 3, 2011]
Marvell Technology Sees Higher Q2 [May 30, 2011]
ECB Good, Federal Reserve Bad [April 7, 2011]
Adobe, Red Hat, Oracle show software leverage [March 28, 2011]
Marvell Technology: What Inflection Point? [March 8, 2011]
Random Investment Illusions [February 21, 2011]
Counting NVIDIA Chickens Before They Hatch? [February 17, 2011]
Better Deal: Akamai or Limelight? [February 15, 2011]
Hansen Medical: Upgrade Due [February 9, 2011]
Paint SGI Black [February 3, 2011]
Gilead Sciences, Antivirals, and Tamiflu [January 26, 2011]
AMD: Fusion Without Dirk Meyer [January 21, 2011]
Nokia N8: CPU, GPU Roles Shift [January 12, 2011]
Dot Hill Jumps on Preliminary Q4 Results [January 10, 2011]
The Recession is Dead [September 1, 2010]
Buying Stocks Low [August 22, 2010]
Bonds, Danger! Bonds, Danger! [April 4, 2010]
The Gold Bubble [November 18, 2009]
Choosing a Biotech Stock series
Inventory Corrections and Short Memories [April 8, 2009]
Have We Hit Bottom Yet? [March 12, 2009]
About OpenIcon and William P. Meyers